Phagos gets €25M boost to combat bacterial diseases

Paris-based biotechnology company Phagos has secured a €25 million Series A funding round, marking a significant advancement in the fight against bacterial diseases. The funding, co-led by several venture capital firms, will enable Phagos to scale its AI-enhanced phage therapy platform, which develops treatments designed to combat antibiotic resistance and improve animal health. This investment underscores the growing interest in innovative solutions to address the global challenge of antimicrobial resistance. Phagos, founded in 2021 by Alexandros Pantalis and Adèle James, leverages artificial intelligence to create tailored bacteriophage therapies. Their AI platform analyzes phage and bacterial genomes to predict interactions, enabling scalable and targeted treatments. The company has already obtained authorization to market personalized phage-based veterinary medicines. The impact of Phagos' technology extends to animal health, which addresses the declining effectiveness of antibiotics since 2000. The company’s approach has broader implications, as bacterial infections are a leading cause of human mortality and contribute significantly to food waste. With the new funding, Phagos aims to expand its team and advance research and development, potentially setting a global standard for phage therapy. Phagos’ success highlights the convergence of AI and biotechnology to address critical health challenges. The company's focus on personalized phage therapies positions it to make a significant contribution to combating antibiotic resistance.